Among patients with end-stage renal disease undergoing living-related kidney transplants, the use of bone-marrow derived mesenchymal (cells that can differentiate into a variety of cell types) stem cells instead of antibody induction therapy resulted in a lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated kidney function at 1 year, according to a study in the March 21 issue of JAMA.
- New protocol streamlines therapy that makes more kidney transplants possibleWed, 16 Jul 2008, 17:28:23 EDT
- Most kidney transplant candidates will accept risk of infectionThu, 25 Mar 2010, 17:27:21 EDT
- Kidneys from deceased donors with acute renal failure expand donor poolThu, 1 Oct 2009, 10:16:07 EDT
- Obtaining kidney transplants abroad carries certain medical risksWed, 15 Oct 2008, 17:42:50 EDT
- 'Nature vs. nurture' study of deceased donor pairs in kidney transplantationWed, 22 Apr 2009, 1:56:28 EDT